OakChart

Prime Medicine Inc

PRMEHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 12:12 PM ET

4.24+0.34 (8.72%)
2026-11-11 18:13 CET
Market cap
- USD m
Revenue, TTM
- USD m
Net income, TTM
- USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-
P/E
-
Compare

Price

PRME against its 20, 50 and 200-day averages
2050200beat
3.004.005.006.007.6M15.2MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PRMEclose 4.2420-day 4.2450-day 3.68200-day 3.504.2452w high52w low

28.3% under the 52-week high of 5.91 on 29 Oct 2026. 52-week low 2.67 on 11 Jun 2026. Last 15 sessions, 74.9% high to low

Profile

PRME
52-week range, 48% of the way up
2.675.91

Prime Medicine, Inc. is a biotechnology company, which engages in developing one-time curative genetic therapies. The company was founded by David R. Liu on September 13, 2019 and is headquartered in Cambridge, MA.

IndexRUT
Employees146
IPOOct 20, 2022
Beta2.19
ATR, 14d0.47
Rel volume4.63
Short float29.91%
Insider own46.28%
Inst own49.60%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap769.04M
Enterprise Value786.45M
Income-187.89M
Sales4.07M
Book/sh0.22
Cash/sh0.52
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees146
IPOOct 20, 2022

Ratios

P/E-
Forward P/E-
PEG-
P/S188.95
P/B19.25
P/C8.09
P/FCF-
EV/EBITDA-
EV/Sales193.23
Quick Ratio3.05
Current Ratio3.05
Debt/Eq2.83
LT Debt/Eq2.60
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.09
EPS next Y-0.94
EPS next Q-0.24
EPS this Y28.21%
EPS next Y2.93%
EPS next 5Y13.58%
EPS past 3/5Y2.55% -91.28%
Sales past 3/5Y- -2.32%
EPS Y/Y TTM32.10%
Sales Y/Y TTM-17.90%
EPS Q/Q41.64%
Sales Q/Q3.50%
EarningsAug 06 BMO
EPS/Sales Surpr.6.69% -48.74%

Ownership

Insider Own46.28%
Insider Trans0.00%
Inst Own49.60%
Inst Trans5.30%
ROA-71.16%
ROE-373.29%
ROIC-131.10%
Gross Margin-81.64%
Oper. Margin-4824.94%
Profit Margin-4613.11%
SMA20-0.02%
SMA5015.19%
SMA20021.01%
Trades-

Technical

Shs Outstand180.74M
Shs Float97.44M
Short Float29.91%
Short Ratio7.04
Short Interest29.15M
52W High5.91 -28.26%
52W Low2.67 58.80%
Volatility10.98% 11.66%
ATR (14)0.47
RSI (14)51.66
Beta2.19
Rel Volume4.63
Avg Volume4.14M
Volume8,516,364

Performance

Perf Week-14.69%
Perf Month27.71%
Perf Quarter33.75%
Perf Half Y29.66%
Perf YTD22.19%
Perf Year8.16%
Perf 3Y-37.69%
Perf 5Y-
Perf 10Y-
Recom1.46
Target Price7.53
Prev Close3.90
Price4.24
Change %8.72%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Aug 25, 2026ResumedCChardan Capital MarketsBuy$7+65.1%
Aug 19, 2026InitiatedBBMO Capital MarketsOutperform$9+112.3%
Jun 29, 2026UpgradeHH.C. WainwrightNeutral → Buy$8+88.7%
Mar 12, 2026InitiatedOOppenheimerOutperform$11+159.4%
May 27, 2025DowngradeCCitigroupBuy → Neutral$1.50-64.6%
May 20, 2025DowngradeJJP MorganOverweight → Neutral
May 20, 2025DowngradeHH.C. WainwrightBuy → Neutral
Dec 10, 2024InitiatedJJMP SecuritiesMkt Outperform$10+135.8%
May 20, 2024InitiatedHH.C. WainwrightBuy$10+135.8%
May 16, 2024UpgradeCCitigroupNeutral → Buy$10+135.8%

Peers

Mkt cap
TickerCompanyMkt cap
BEAMBeam Therapeutics Inc2.61B
NTLAIntellia Therapeutics Inc1.59B
EDITEditas Medicine Inc375.49M
CRSPCRISPR Therapeutics AG4.39B
WVEWave Life Sciences Inc672.55M
DTILPrecision Biosciences Inc254.73M
KRROKorro Bio Inc213.50M
SANASana Biotechnology Inc701.17M
QUREuniQure NV1.64B
RGNXRegenxbio Inc550.06M

Held by

AUM
TickerCompanyAUM
ARKGARK Genomic Revolution ETFAUM: 1.97B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
IBBiShares Biotechnology ETFAUM: 11.36B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B

News

latest 14 of 206
  • Prime Medicine Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -9.30% +8.72%
  • Prime Medicine Announces Proposed $125.0 Million Public Offering of Common Stock (GlobeNewswire)
  • Prime Medicine to Present at Jefferies Global Healthcare Conference (GlobeNewswire) -7.53%
  • PRME, BEAM, EDIT, NTLA, CRSP Stocks Gain As FDA Signals Faster Route For Patient-Specific Gene Edits (Stocktwits) +23.22%
  • Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease (GlobeNewswire) +7.72%
  • Loading…
  • Prime Medicine stock surges on FDA IND clearance (Investing.com) -5.54%
  • Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency (GlobeNewswire)
  • Anthropic AI Discovery Gene-Editing Stocks Falling (GuruFocus.com)
  • CRSP, NTLA, BEAM, PRME, EDIT Shares Slip Did Claude Just Spook Gene-Editing Stocks? (Stocktwits) -11.58%
  • Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire)
  • Scribe's Genetic Editing Aims to Prevent Heart Attacks (Barrons.com)
  • Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease (GlobeNewswire)
  • Cathie Wood Dumps AMD, Doubles Down on Meta Stock (GuruFocus.com) -10.64%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
No quarterly earnings.

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2022FY-4.190-4.180-1.4610.004.00
2023FY-2.180-1.898-2.1780.004.44
2024FY-1.650-1.600-1.6522.9811.55
2025FY-1.350-1.339-1.3504.634.97
2026FY--0.969--9.20
2027FY--0.941--11.01
2028FY--0.871--21.36
2029FY--0.944--15.23
2030FY--0.881--58.69

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
No estimate revisions.

Estimate history

EPS, annual-0.029-0.053-1.923-1.461-2.178-1.652-1.352-1.0854
Period2019202020212022202320242025TTM
EPS, quarterly-0.464-0.439-0.357-0.397-0.407-0.315-0.255-0.277-0.238
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual05.210002.9834.6324.07
Period2019202020212022202320242025TTM
Sales, quarterly00.2092.1831.4541.1151.2250.8380.8561.154
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual95.7395.73100.76897.20997.377131.161180.514180.738
Period2019202020212022202320242025MRQ
Shares, quarterly120.031131.161131.161131.161134.494180.309180.514180.616180.738
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

No statement data.

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue1.150.860.841.231.111.452.180.21
Cost of Goods Sold Incl. D&A1.781.861.881.881.861.701.721.56
Gross Profit-0.63-1.00-1.04-0.66-0.75-0.250.47-1.35
Selling, General and Administrative Excl. Other42.6549.6547.5753.3252.6352.1544.6952.88
Research and Development33.4034.1034.7143.9941.3840.5634.1040.34
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-43.28-50.65-48.61-53.97-53.38-52.39-44.22-54.23
Interest Expense0.000.000.000.000.000.000.000.00
Unusual Expense-0.00-0.54-1.450.511.06-0.06-0.21
Net Income Before Taxes-42.11-49.12-46.08-50.58-52.59-51.89-42.28-52.52
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-42.11-49.12-46.08-50.58-52.59-51.89-42.28-52.52
Net Income From Continuing Operations-42.11-49.12-46.08-50.58-52.59-51.89-42.28-52.52
Net Income-42.11-49.12-46.08-50.58-52.59-51.89-42.28-52.52
EPS (Recurring)-0.24-0.28-0.26-0.32-0.40-0.39-0.36-0.44
EPS (Basic, Before Extraordinaries)-0.24-0.28-0.26-0.32-0.41-0.40-0.36-0.44
EPS (Diluted)-0.24-0.28-0.26-0.32-0.41-0.40-0.36-0.44
EBITDA-41.50-48.80-46.73-52.09-51.51-50.69-42.51-52.67
Non-Operating Income (Expense)1.181.531.991.941.291.561.891.50
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense4.874.644.5112.756.335.685.946.83
Price To Sales Ratio160.56152.78135.23148.7764.3267.72116.10579.36
Gross Margin-54.68-116.82-123.87-53.55-67.17-16.9221.35-645.45
Operating Margin-3,750.87-5,917.52-5,800.48-4,405.96-4,787.17-3,603.30-2,025.74-25,948.33
Net Margin-3,648.96-5,738.55-5,498.69-4,129.14-4,716.68-3,568.78-1,936.60-25,128.23
Shares Outstanding180.74180.62180.51180.31134.49131.16131.16131.16
Market Capitalization707.37628.32626.37987.21324.30261.01382.99464.52

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY
Cash & Short Term Investments177.68190.44121.67293.92269.6253.33-
Short Term Receivables0.000.000.000.000.000.00-
Inventories0.000.000.000.000.000.00-
Other Current Assets3.6121.4421.312.700.960.07-
Total Current Assets181.29211.89142.98296.62270.5853.40-
Net Property, Plant & Equipment146.7571.5636.6048.5515.680.60-
Total Investments and Advances13.6914.0613.5013.5013.120.00-
Intangible Assets-0.00-----
Deferred Tax Assets273.90192.63123.0470.60---
Other Assets1.000.000.781.652.470.79-
Total Assets616.64490.14316.89430.91301.8654.78-
Short Term Debt Incl. Current Port. of LT Debt8.143.619.2811.697.340.00-
Accounts Payable8.8911.3519.544.331.440.25-
Other Current Liabilities20.4223.0027.6110.6949.2119.19-
Total Current Liabilities37.4537.9656.4226.7157.9819.44-
Long Term Debt108.2937.184.3617.053.070.00-
Provision for Risks Charges0.000.000.000.000.000.00-
Deferred Tax Liabilities273.90192.63123.0470.881.241.87-
Other Liabilities76.1369.220.000.000.000.00-
Total Liabilities495.77336.99183.82114.6462.3021.31-
Non-Equity Reserves0.000.000.000.000.000.00-
Preferred Stock - Carrying Value0.000.000.000.00395.8031.14-
Common Equity120.87153.15133.07316.27-156.242.34-
Total Shareholders Equity120.87153.15133.07316.27239.5633.47-
Accumulated Minority Interest0.000.000.000.000.000.00-
Total Equity120.87153.15133.07316.27239.5633.47-
Total Liabilities & Stockholders Equity616.64490.14316.89430.91301.8654.78-
Book Value Per Share0.671.171.373.25-1.550.02-
Tangible Book Value Per Share0.671.171.373.25-1.550.02-
Full-Time Employees14621423417581--
Price to Book Ratio17.712.024.45-8.10-8.10--
Return on Assets-36.35-48.54-52.99-33.25-92.74--
Return on Equity-146.81-136.88-88.19-43.83-121.13--
Return on Invested Capital-87.77-102.92-144.17-36.55-68.16-10.19-
Quick Ratio4.845.582.5311.104.672.75-
Current Ratio4.845.582.5311.104.672.75-

Cash flow, annual

No statement data.

Balance sheet, quarterly

No statement data.

Cash flow, quarterly

No statement data.

Revenue breakdown

Biological Products, (No Diagnostic Substances)2024: 2.98M 2025: 4.63M
United States2024: 2.98M 2025: 4.63M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
No short interest data.

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.503.304.300.0029.0590.000.000.987-0.0120.000
call1.002.803.800.0015.2030.000.000.977-0.0120.000
call1.502.303.300.0010.6300.000.000.967-0.0120.000
call2.001.802.801.508.08310.000.000.955-0.0120.001
call2.501.302.300.006.2460.000.000.912-0.0180.001
call3.000.751.751.904.63574.000.000.880-0.0160.001
call3.500.251.250.623.45932.001.000.765-0.0260.002
call4.000.400.650.542.0201,8291630.635-0.0280.003
call4.500.250.350.251.6576431510.505-0.0320.003
call5.000.050.350.102.3145,0002.000.391-0.0330.003
call5.500.001.000.121.7841050.000.239-0.0210.002
call6.000.000.100.042.1454440.000.211-0.0230.002
call7.000.000.500.102.7142560.000.180-0.0270.002
call8.000.000.100.104.0972.000.000.224-0.0420.002
call9.000.001.000.003.4470.000.000.116-0.0220.001
call10.000.000.500.003.73961.000.000.110-0.0230.001
put0.500.000.050.008.4730.000.00-0.015-0.0100.000
put1.000.001.000.005.5740.000.00-0.026-0.0110.000
put1.500.001.000.004.4880.000.00-0.032-0.0120.000
put2.000.000.050.042.9463.000.00-0.052-0.0100.001
put2.500.001.000.003.0050.000.00-0.125-0.0200.001
put3.000.000.100.052.1066430.00-0.175-0.0180.002
put3.500.000.250.202.24616.00500-0.237-0.0250.002
put4.000.100.400.251.98172626.00-0.368-0.0280.003
put4.500.201.200.753.5643490.00-0.510-0.0300.003
put5.000.701.101.032.2794900.00-0.608-0.0320.003
put5.500.801.801.603.7191.000.00-0.648-0.0370.002
put6.001.252.251.454.12711.000.00-0.835-0.0170.002
put7.002.303.302.354.5931.000.00-0.861-0.0200.001
put8.003.404.400.005.5200.000.00-0.875-0.0210.001
put9.004.305.300.005.1370.000.00-0.885-0.0230.001
put10.005.306.300.005.9350.000.00-0.892-0.0240.001

Latest SEC filings

0
FiledFormDescriptionPeriodLink
No filings.

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Alphabet Inc.9.13%
BlackRock, Inc.5.32%
ARK Investment Management LLC4.62%
STATE STREET CORP4.19%
T. Rowe Price Investment Management, Inc.2.90%
VANGUARD CAPITAL MANAGEMENT LLC2.50%
BALYASNY ASSET MANAGEMENT L.P.2.20%
GOLDMAN SACHS GROUP INC1.90%
Casdin Capital, LLC1.75%
Woodline Partners LP1.66%

Funds

Fund% owned
ARK Genomic Revolution ETF4.16%
State Street(R) SPDR(R) S&P(R) Biotech ETF2.89%
VANGUARD TOTAL STOCK MARKET INDEX FUND1.73%
ARK Venture Fund1.63%
iShares Russell 2000 ETF1.39%
T. Rowe Price Small-Cap Value Fund, Inc.0.75%
VANGUARD EXTENDED MARKET INDEX FUND0.72%
T. Rowe Price Small-Cap Stock Fund, Inc.0.68%
Fidelity Small Cap Index Fund0.57%
T. Rowe Price Institutional Small-Cap Stock Fund0.43%

OakChart. PRME. Cached 15 minutes.

Some panels did not load: insider, si, ea, lf, dv.